Two indications.
One film. One pilot.
Project Lucid is the first clinical program testing a sublingual esketamine film with PTSD as the primary indication and autoimmune disease as an adjunctive indication — from a single Phase 1/2 pilot. 505(b)(2) pathway confirmed. LTS Lohmann GMP manufacturing active. Human PK established. IRB-ready, Q4 2026 enrollment.
What it is, who it helps, and why it's a two-shots-on-goal asset.
- The drug. 50mg sublingual esketamine film (LTS Lohmann). Bioequivalent Cmax to Spravato 56–84mg intranasal with a metabolite profile favoring synaptogenesis over dissociation.
- The two indications. PTSD primary ($3.5B market, no biologic holds the label) + autoimmune adjunctive ($120B market, same cytokines as Skyrizi / Cosentyx / Humira).
- Why one trial. PTSD patients carry 2× the autoimmune-disease burden (O'Donovan 2015, N=666,269). Wellington 2025 proved oral ketamine modulates IL-17, IFN-α/β, and cytokine-storm pathways in PTSD. One pilot reads out on both.
- The regulatory path. 505(b)(2) confirmed by FDAMap. Anchors to Spravato's safety package — no new animal tox. At-home delivery unlocked via non-inferiority vs. the Spravato REMS using validated digital monitoring.
- The defensible label. Flexible-dose tiles (26/39/52/65/78/90mg) within one product — a Phase 3 differentiator grounded in ketamine's inverted-U dose response.
- The ask. $2.5M SAFE on $12M pre-money cap. Funds Phase 1/2 (N=12), expanded biomarker panel, at-home REMS concordance dataset, and IND filing.
- The exit. Series A $15–25M post Phase 1 (Q4 2027); strategic interest from generic esketamine holders (Teva) and immunology-shelf acquirers on autoimmune signal. Transcend (MDMA analog) sold for ~$1.2B.
- The team. Richard Idell, MD — Dallas psychiatrist, Sponsor-Investigator. Advisors: Mukesh Kumar (FDAMap, 150+ trials); Steven Idell (40y NIH, Lung Therapeutics acquired); EMMES CRO; Neurolivd (patient voice).
The window has never been wider — and the cleanest lane is open.
The post-Lykos landscape has re-prioritized psychiatric assets with clean, placebo-controlled evidence packages. Ketamine's RCT record in PTSD is exactly that. No approved biologic holds the PTSD primary indication. No novel mechanism has been approved in 25 years. And oral ketamine is the first oral NMDA antagonist with transcriptomic evidence of modulating the same cytokines as the immunology shelf's top sellers.
Pre-IND seed SAFE
Series A target $15–25M post-Phase 1 (Q4 2027). Check size and subscription details on request. Dual funding path: non-dilutive DoD/VA grants (CDMRP TBIPHRP up to $2.1M; NIMH SBIR) pursued alongside equity.
Everything an analyst needs in one place.
Open documents for review. For full access including financial model, protocol redline, IP file, and IND readiness memo, contact investors@lucidptsd.com.
Built by operators with regulatory scars.
Let's talk.
Thirty minutes to walk through the thesis, the evidence, and the ask. If we're the wrong fit for your fund, we'd still welcome an intro to someone who is.
This page is for informational purposes only and does not constitute an offer to sell or solicitation of an offer to buy any security. Any offering will be made only through definitive documentation. Forward-looking statements regarding clinical and regulatory outcomes are subject to risk. Not medical advice.